Skip to main content
SpringerLink
Log in
Book cover

Apport des neurosciences à la psychiatrie clinique pp 173–184Cite as

Psychopharmacologie : quels seront les médicaments psychotropes de demain ?

  • Chapter

  • 432 Accesses

Résumé

Le développement des médicaments psychotropes comme celui des autres classes de médicaments a subi un coup d’arrêt depuis une dizaine d’années pour plusieurs raisons qui ne sont souvent pas connues des psychiatres.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Becker RE, Greig NH (2010) Lost in translation: neuropsychiatric drug development. Sci Transl Med 2(61): 61rv6

    Article  PubMed  CAS  Google Scholar 

  2. Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12: 88–118

    Article  PubMed  CAS  Google Scholar 

  3. Kar G, Keskin O, Gursoy A, Nussinov R (2010) Allostery and population shift in drug discovery. Curr Opin Pharmacol 10: 715–22

    Article  PubMed  CAS  Google Scholar 

  4. Burford NT, Watson J, Bertekap R, Alt A (2011) Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81: 691–702

    Article  PubMed  CAS  Google Scholar 

  5. De Lean A, Stadel J, Lefkowitz J (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 255: 7108–17

    PubMed  Google Scholar 

  6. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16: 89–97

    Article  PubMed  CAS  Google Scholar 

  7. Kenakin T (1995) Agonist receptor efficacy II; agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232–8

    Article  PubMed  CAS  Google Scholar 

  8. Salahpour A, Angers S, Bouvier M (2000) Functional significance of Oligomerization of G-protein-coupled receptors. Trends in Endocrinology and metabolism 11: 163–8

    Article  PubMed  CAS  Google Scholar 

  9. Massot O, Rousselle JC, Fillion MP, et al. ( 1999) 5-Hydroxytryptaminemoduline, a new endogenous cerebral peptide, controls the serotonergic activity its specific interaction with 5-HT1B/D receptors. Mol Pharmacol 50: 752–62

    Google Scholar 

  10. Clénet F, Hascoët M, Fillion G, et al. (2005) Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 158: 339–48

    Article  PubMed  CAS  Google Scholar 

  11. Hedlund P, Carson M, Sutcliffe G, Thomas E (1999) Allosteric regulation of the binding properties of 5-Hydroxytryptamine7 receptor. Biochem Pharmacol 58: 1807–13

    Article  PubMed  CAS  Google Scholar 

  12. Grazzini E, Guillon G, Mouillac B, Zingg HH (1998) Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392: 509–12

    Article  PubMed  CAS  Google Scholar 

  13. Canals M, Sexton PM, Christopoulos A (2011) Allostery in GPCRs: ‘MWC’ revisited. Trends Biochem Sci 36: 663–72

    Article  PubMed  CAS  Google Scholar 

  14. Nussinov R, Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153: 293–305

    Article  PubMed  CAS  Google Scholar 

  15. Thathiah A, Horré K, Snellinx A, et al. (2013)-arrestin 2 regulates A generation and — secretase activity in Alzheimer’s disease. Nature Medicine 19: 43–9

    Article  PubMed  CAS  Google Scholar 

  16. Jiang T, Yu JT, Tan MS, et al. (2013)-Arrestins as Potential Therapeutic Targets for Alzheimer’s Disease. Mol Neurobiol [Epub ahead of print]

    Google Scholar 

  17. Heikkinen T, Lehtimäki K, Vartiainen N, et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One 7(12): e50717

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Kehler J (2013) Phosphodiesterase 10A inhibitors: a 2009–2012 patent update. Expert Opin Ther Pat 23: 31–45

    Article  PubMed  CAS  Google Scholar 

  19. Raheem IT, Breslin MJ, Fandozzi C, et al. (2012) Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 22: 5903–8

    Article  PubMed  CAS  Google Scholar 

  20. Hasan A, Mitchell A, Schneider A, et al. (2013) Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci 263: 273–84

    Article  PubMed  Google Scholar 

  21. Day JJ, Sweatt JD (2012) Epigenetic treatments for cognitive impairments. Neuropsychopharmacology 37: 247–60

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  22. Kurita M, Holloway T, García-Bea A, et al. (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15: 1245–54

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Abbott BD (2009) Review of the expression of peroxisome proliferator activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27: 246–57

    Article  PubMed  CAS  Google Scholar 

  24. Bordet R, Ouk T, Petrault O, et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34(Pt6): 1341–6

    PubMed  CAS  Google Scholar 

  25. Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferatoractivated receptors and inflammation. Pharmacol Ther 110: 371–85

    Article  PubMed  CAS  Google Scholar 

  26. Cimini A, Benedetti E, Cristiano L, et al. (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130: 325–37

    Article  PubMed  CAS  Google Scholar 

  27. Le Foll B, Di Ciano P, Goldberg SR, Ciccocioppo R (2013) Peroxisome Proliferator Activated Receptors (PPAR) Agonists As Promising New Medications For Drug Addiction. Curr Drug Targets 14: 768–76

    Article  PubMed  Google Scholar 

  28. Salvador-Carulla L, Mezzich JE (2012) Person-centred medicine and mental health. Epidemiol Psychiatr Sci 21: 31–7

    Article  Google Scholar 

  29. Bourin M (1997) Animal models of anxiety: are they suitable for predicting drug action in humans? Pol J Pharmacol. 49: 79–84

    PubMed  CAS  Google Scholar 

  30. Yonutas HM, Sullivan PG (2013) Mechanism of Action of PPAR Agonists in CNS Injury. Curr Drug Targets 14(7): 733–42

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de pharmacologie clinique, Université de Nantes, 1, place Alexis Ricordeau, 44093, Nantes Cedex 1, France

    M. Bourin

Authors
  1. M. Bourin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bourin .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Bourin, M. (2014). Psychopharmacologie : quels seront les médicaments psychotropes de demain ?. In: Apport des neurosciences à la psychiatrie clinique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0505-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0505-4_10

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0504-7

  • Online ISBN: 978-2-8178-0505-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation